Back

Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review

Senefeld, J.; Klassen, S. A.; Ford, S. K.; Wiggins, C. C.; Bostrom, B. C.; Thompson, M. A.; Baker, S. E.; Nicholson, W. T.; Johnson, P. W.; Carter, R. E.; Henderson, J. P.; Hartman, W. R.; Pirofski, L.-a.; Wright, R. S.; Fairweather, D.; Bruno, K. A.; Paneth, N. S.; Casadevall, A.; Joyner, M. J.

2020-11-10 infectious diseases
10.1101/2020.11.08.20224790 medRxiv
Show abstract

0In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.